Pharma News

AIDS Healthcare Foundation (AHF), the largest global AIDS organization and a vocal critic of runaway drug pricing and drug profiteering, blasted Gilead Sciences, Inc. over newly instituted price hikes of 6.9% on three key HIV/AIDS treatments despite the fact that the patent for a key component of each treatment—tenofovir—expired in mid-December.

[adsense:336x280:8701650588]

Biosimilar Trastuzumab, co-developed by Biocon Ltd. and Mylan N.V. has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.

Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited, has received the final approval from the USFDA to market Valacyclovir Tablets USP in strengths of 500 mg and 1 gm.

Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announces the launch of its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘MaburaTM’ in India. The product will be marketed and distributed by Hetero Healthcare in the country.

Attention-deficit/hyperactivity disorder (ADHD) increases the risk of subsequent sexually transmitted infections (STIs) among adolescent and young adult populations by about three times, reports a study published in the January 2018 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP)

Scientists have shown how alcohol damages DNA in stem cells, helping to explain why drinking increases your risk of cancer, according to research part-funded by Cancer Research UK and published in Nature today.

[adsense:336x280:8701650588]

The U.S. Food and Drug Administration permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.

Teva Pharmaceutical Industries Ltd announced the exclusive launch of a generic version of Reyataz®1 (atazanavir) capsules in the U.S.

Lupin announced that it has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (FDA) to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products Ltd.

Rhizen  Pharmaceuticals S.A., an nounced  that the U.S. Food and Drug Administration  (FDA) has granted orphan - drug designation for  the active moiety of Tenalisib  (RP6530),  the Company’s  highly selective and orally active  dual PI3K delta/gamma  inhibitor, for treatment of  peripheral T - cell l ymphoma  (PTCL).